Organization · Venture Capital
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm focused on life sciences, specifically investing in technologies and services that support the biopharmaceutical industry.
Overview
What Dynamk Capital does
What Dynamk Capital is
Dynamk Capital is a New York-based venture capital firm focused on life sciences, specifically investing in technologies and services that support the biopharmaceutical industry.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2016
- Approximate age
- About 10 years
- Structured capabilities
- Funder
- Last reviewed
- March 31, 2026
Official channels
Find Dynamk Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Dynamk Capital as a funder
Investment thesis
Dynamk Capital invests in disruptive technologies, tools, and services enabling the full biopharma continuum: drug discovery, clinical development, and manufacturing of biotherapeutics, with particular emphasis on cell & gene therapies and vaccines.
Focus narrative
Dynamk Capital invests in life sciences, specifically targeting start-ups that provide technologies and services to the biopharma sector. Their investment thesis includes a focus on biotechnology, cell and gene therapies, vaccines, and regenerative medicine.
Value beyond capital
Dynamk Capital provides hands-on commercialization and exit support through a team of entrepreneurs and industry executives, enhancing the growth and success of its portfolio companies.
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 13
Portfolio context
Dynamk Capital's portfolio includes notable companies such as: bit.bio (human cell manufacturing), Alpenglow Biosciences (3D tissue imaging), Curi Bio (preclinical discovery platform), CellFE Biotech (gene-editing payloads), Bionter AG (analytical testing solutions), and RoosterBio (clinical stage cell therapy production).
Common questions
What to know about Dynamk Capital
Upseed classifies Dynamk Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 31, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.